Article content material
OKLAHOMA CITY, March 11, 2023 (GLOBE NEWSWIRE) — Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract growth and manufacturing group (CDMO), and Phenotypeca Restricted (Phenotypeca), a analysis and growth group with proprietary yeast expression expertise that gives key benefits in recombinant protein manufacture, have entered into an settlement to supply optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing. The collaboration between Cytovance Biologics and Phenotypeca is anticipated to speed up the event of high-performance yeast strains and to enhance the effectivity of biologics manufacturing for biopharma purchasers by leveraging Cytovance Biologics’s intensive data in microbial fermentation and Phenotypeca’s yeast pressure growth expertise to provide prime quality expressing cell traces. This collaboration extends Cytovance Biologics’ management in manufacturing microbial-derived energetic pharmaceutical components (API) from finish to finish and expands Phenotypeca’s industrial attain.
Article content material
Saccharomyces cerevisiae is extensively used within the biopharmaceutical trade for the secure manufacturing of therapeutic proteins and different biologics, the pressure breeding and genomic proprietary expertise of Phenotypeca brings a brand new period of further capabilities to this established expertise. Saccharomyces cerevisiae is nicely suited to make sure varieties of human proteins and will be harnessed as tiny, environment friendly factories for producing biopharmaceuticals. Greater than 20 biopharmaceutical merchandise have already been authorised by the FDA utilizing Saccharomyces cerevisiae because the manufacturing organism. This new relationship will enable Cytovance Biologics to supply international biopharma purchasers with service of end-to-end microbial fermentation course of from early-phase course of growth to late part manufacturing by leveraging Phenotypeca’s yeast pressure growth capabilities and its superior expertise platform.
Article content material
“This collaboration is an thrilling alternative to leverage Phenotypeca’s experience in yeast pressure growth to reinforce our microbial capabilities. We stay up for working with Phenotypeca to develop high-performance Saccharomyces cerevisiae strains and advance the biologic by means of product lifecycle,” mentioned Ping Zhang, CEO of Cytovance Biologics.
“Our expertise platform has the potential to considerably enhance the effectivity and yield of biologics manufacturing, and we’re excited to collaborate with Cytovance Biologics to deliver our expertise to new companions,” mentioned Johnny Cordiner, CEO of Phenotypeca.
For extra data, please go to www.cytovance.com and www.phenotypeca.com.
About Cytovance Biologics
Article content material
Cytovance Biologics, Inc. (Cytovance Biologics) is a number one biopharmaceutical contract growth and manufacturing group (CDMO) that excels within the fast and cost-effective growth and manufacture of enormous molecule energetic pharmaceutical components (APIs). Cytovance Biologics makes use of each mammalian cell tradition and microbial fermentation to precise monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines, and different organic merchandise, together with plasmid DNA and cell-based therapeutics. Along with its medical and industrial CGMP API manufacturing providers, Cytovance Biologics gives well-integrated growth providers supporting your complete product lifecycle, together with cell line growth, cell banking, microbial pressure growth, course of and analytical growth, and course of characterization. Our state-of-the-art services in Oklahoma Metropolis are designed to fulfill United States, European Union, and different international regulatory requirements.
Cytovance Biologics gives deep trade experience and distinctive custom-made providers for the scale-up and CGMP manufacture of protein-based therapeutics; from early-stage pre-clinical growth to industrial manufacturing, for each mammalian and microbial. Additional data will be discovered at www.cytovance.com.
Cytovance Biologics, your responsive, dependable, and resourceful companion.
Media Contact:
Ruofu Huang
Tel: 405-319-8310
E-mail: advertising and [email protected]
